BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 35085002)

  • 21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
    Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen.
    Kuppermann D; Calais J; Marks LS
    J Urol; 2022 Apr; 207(4):769-778. PubMed ID: 35085002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
    Hofman MS; Iravani A
    PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS; Hicks RJ; Maurer T; Eiber M
    Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T; Gschwend JE; Eiber M
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of
    Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New aspects of molecular imaging in prostate cancer.
    Ceci F; Castellucci P; Cerci JJ; Fanti S
    Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of PSMA PET-CT in patients with metastatic prostate cancer].
    von Hardenberg J; Büsing KA; Nuhn P; Ritter M
    Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Fitzpatrick C; Lynch O; Marignol L
    Anticancer Res; 2017 Jun; 37(6):2753-2760. PubMed ID: 28551611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [
    Evangelista L; Maurer T; van der Poel H; Alongi F; Kunikowska J; Laudicella R; Fanti S; Hofman MS
    Eur Urol Oncol; 2022 Jun; 5(3):273-282. PubMed ID: 35367165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
    Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N
    Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of
    Bailey J; Piert M
    Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.